You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 29, 2024

Litigation Details for Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action)
The small molecule drug covered by the patents cited in this case is ⤷  Sign Up .

Details for Picone v. Shire U.S. Inc. (Indirect Purchaser Antitrust Class Action) (D. Mass. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-11-22 1 method-of-use patent, and U.S. Patent Nos. 6,287,599 (‘599 Patent) and 6,811,794 (‘794 Patent), which cover…Shire’s Intuniv patent portfolio consists of U.S. Patent Nos. 5,854,290 (‘290 Patent), which is a now-invalidated…applied a patent procurement strategy known as “evergreening.” “Evergreened” patents are patents not on …method-of-use patent (‘290 Patent) of guanfacine hydrochloride and two extended release formulation patents (‘599…-of-Use Patent 57. Shire asserted all three (3) patents, including the ‘290 Patent, against External link to document
2017-10-31 102 5,854,290 (the ’290 patent), 6,287,599 (the ’599 patent), and 6,811,794 (the ’794 patent), the terms of which…5,854,290 (the ’290 patent), 6,287,599 (the ’599 patent), and 6,811,794 (the ’794 patent), the terms of which…that ’290 patent was a method-of-use patent. Shire denies any characterization of those patents, and denies…under three patents that covered Intuniv and that were listed in the Orange Book: U.S. Patent Nos. 5,854,290…under three patents that cover Intuniv and that were listed in the Orange Book: U.S. Patent Nos. 5,854,290 External link to document
2020-10-09 343 Memorandum & Order “the ’290 Patent”), 4 6,287,599 (“the ’599 Patent”), 5 and 6,811,794 (“the ’794 Patent” and, collectively…collectively with the ’290 Patent and the ’599 Patent, “the Patents”). 6 [FWK 380-1 ¶ 26; FWK 374-1 ¶ 3]. …hearing on the Patents on February 14, 2012. [FWK No. 380-1 ¶ 37]. The ’599 Patent and ’794 Patent each reference…Shire listed three patents in the FDA Orange Book as covering Intuniv: U.S. Patent Nos. 5,854,290 (“the…’290 Patent in March 2012. [FWK 380-1 ¶ 27; FWK 374-1 ¶ 19]. Plaintiffs maintain that the patent was abandoned External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.